Gene therapy for the peripheral nervous system: A strategy to repair the injured nerve?

Current Gene Therapy

Volumn 11, Issue 2, 2011, Pages 75-89

  Mason, Matthew R J ^a   Tannemaat, Martijn R ^a,b   Malessy, Martijn J A ^a,b   Verhaagen, Joost ^a,c  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

AAV; Adenovirus; DRG; Gene therapy; HSV; Lentivirus; Motor neurons; Nerve injury; Pns

Indexed keywords

ADENOVIRUS VECTOR; BETA ENDORPHIN; BETA GALACTOSIDASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CELL ADHESION MOLECULE; ENDOMORPHIN 2; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEIN; HERPES SIMPLEX VIRUS VECTOR; INTERLEUKIN 10; LENTIVIRUS VECTOR; LYSOPHOSPHATIDYLCHOLINE; MORPHINE; MU OPIATE RECEPTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; PARVOVIRUS VECTOR; PREPROENKEPHALIN; PREPROENKEPHALIN A; SCATTER FACTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VESICULAR STOMATITIS VIRUS GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

FIBROBLAST; GENE VECTOR; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; LYSOSOME STORAGE DISEASE; MOTONEURON; MUTAGENESIS; NERVE CELL; NERVE REGENERATION; NERVE SURGERY; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NERVE INJURY; PERIPHERAL NERVOUS SYSTEM; REVIEW; RODENT; SCHWANN CELL; SENSORY NERVE CELL; SPINAL GANGLION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENETICS; HUMAN; LENTIVIRINAE; METABOLISM; PERIPHERAL NERVOUS SYSTEM DISEASES;

ANIMALS; DEPENDOVIRUS; GENE THERAPY; HUMANS; LENTIVIRUS; NERVE REGENERATION; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; SCHWANN CELLS; SENSORY RECEPTOR CELLS; GENETIC THERAPY; PERIPHERAL NERVE INJURIES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; RODENTIA; SIMPLEXVIRUS;

EID: 79953022764     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652311794940764     Document Type: Review

References (183)

1. Hoke A, Brushart T. Introduction to special issue: Challenges and opportunities for regeneration in the peripheral nervous system. Exp Neurol 2010; 223: 1-4.
2. Hoke A. Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans? Nat Clin Pract Neurol 2006; 2: 448-454.
3. Tannemaat MR, Boer GJ, Eggers R, Malessy MJ, Verhaagen J. From microsurgery to nanosurgery: how viral vectors may help repair the peripheral nerve. Prog Brain Res 2009; 175: 173-186.
4. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-169.
5. Ho DY, Mocarski ES. Beta-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infectedmouse. Virology 1988; 167: 279-283.
6. Dobson AT, Sederati F, vi-Rao G, et al. Identification of the latency-associated transcript promoter by expression of rabbit betaglobin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus. J Virol 1989; 63: 3844-3851.
7. Hoke A, Gordon T, Zochodne DW, Sulaiman OA. A decline in glial cell-line-derived neurotrophic factor expression is associatedwith impaired regeneration after long-term Schwann cell denervation. Exp Neurol 2002; 173: 77-85.
8. Sulaiman OA, Midha R, Munro CA, Matsuyama T, Al-Majed A, Gordon T. Chronic Schwann cell denervation and the presence of asensory nerve reduce motor axonal regeneration. Exp Neurol 2002;176: 342-354.
9. Mears S, Schachner M, Brushart TM. Antibodies to myelin associated glycoprotein accelerate preferential motor reinnervation. J Peripher Nerv Syst 2003; 8: 91-99.
10. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a neweucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
11. Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci 1991; 2: 320-330.
12. Federoff HJ, Geschwind MD, Geller AI, Kessler JA. Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA 1992; 89: 1636-1640.
13. Geschwind MD, Kessler JA, Geller AI, Federoff HJ. Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective herpes simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector. Brain Res Mol Brain Res 1994; 24: 327-335.
14. Xu H, Federoff H, Maragos J, Parada LF, Kessler JA. Viral transduction of trkA into cultured nodose and spinal motor neurons conveys NGF responsiveness. Dev Biol 1994; 163: 152-161.
15. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996;70: 7190-1797.
16. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
17. Epstein AL. HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties--a review. Mem InstOswaldo Cruz 2009; 104: 399-410.
18. Palella TD, Hidaka Y, Silverman LJ, Levine M, Glorioso J, Kelley WN. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene 1989; 80: 137-144.
19. Palella TD, Silverman LJ, Schroll CT, Homa FL, Levine M, Kelley WN. Herpes simplex virus-mediated human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal cells. Mol Cell Biol 1988; 8: 457-460.
20. Ho DY, Mocarski ES. Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse. Proc Natl Acad Sci USA 1989; 86: 7596-7600.
21. Davar G, Kramer MF, Garber D, et al. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J Comp Neurol 1994; 339: 3-11.
22. Antunes Bras JM, Epstein AL, Bourgoin S, Hamon M, Cesselin F, Pohl M. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998; 70:1299-303.
23. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkep halinencoding herpes virus. Proc Natl Acad Sci USA 1999; 96: 3211-3216.
24. Yeomans DC, Lu Y, Laurito CE, et al. Recombinant herpes vectormediated analgesia in a primate model of hyperalgesia. Mol Ther 2006; 13: 589-597.
25. Meunier A, Latremoliere A, Mauborgne A, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 2005; 11: 608-616.
26. Yeomans DC, Jones T, Laurito CE, Lu Y, Wilson SP. Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin. Mol Ther 2004; 9: 24-29.
27. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21: 7881-7888.
28. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT. A latent, nonpathogenic HSV-1-derived vector stably expresses betagalactosidase in mouse neurons. Neuron 1990; 5: 353-360.
29. Coffin RS, MacLean AR, Latchman DS, Brown SM. Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors. Gene Ther 1996; 3: 886-891.
30. Chiocca EA, Choi BB, Cai WZ, et al. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol 1990; 2: 739-746.
31. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001; 8: 551-556.
32. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther 2009; 17: 13-18.
33. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. HSV mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther 2003; 8: 367-375.
34. Zhang G, Mohammad H, Peper BD, Raja S, Wilson SP, Sweitzer SM. Enhanced peripheral analgesia using virally mediated gene transfer of the mu-opioid receptor in mice. Anesthesiology 2008; 108: 305-313.
35. Hao S, Wolfe D, Glorioso JC, Mata M, Fink DJ. Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain 2009; 13: 380-386.
36. Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther 2009; 16: 455-460.
37. Palmer JA, Branston RH, Lilley CE, et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol 2000; 74: 5604-5618.
38. Chattopadhyay M, Wolfe D, Mata M, Huang S, Glorioso JC, Fink DJ. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther 2005; 12: 307-313.
39. Anesti AM, Peeters PJ, Royaux I, Coffin RS. Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res 2008; 36: e86.
40. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet 1993; 3: 229-234.
41. Akli S, Caillaud C, Vigne E, et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3: 224-228.
42. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3: 219-223.
43. Le Gal La SG, Robert JJ, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988-990.
44. Dijkhuizen PA, Hermens WT, Teunis MA, Verhaagen J. Adenoviral vector-directed expression of neurotrophin-3 in rat dorsal root ganglion explants results in a robust neurite outgrowth response. J Neurobiol 1997; 33: 172-184.
45. Smith GM, Hale J, Pasnikowski EM, Lindsay RM, Wong V, Rudge JS. Astrocytes infected with replication-defective adenovirus containing a secreted form of CNTF or NT3 show enhanced support of neuronal populations in vitro. Exp Neurol 1996; 139: 156-166.
46. Ghadge GD, Roos RP, Kang UJ, et al. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther 1995; 2: 132-137.
47. Finiels F, Ribotta M, Barkats M, et al. Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases. Neuroreport 1995; 7: 373-378.
48. Warita H, Abe K, Setoguchi Y, Itoyama Y. Expression of adenovirus-mediated E. coli lacZ gene in skeletal muscles and spinal motor neurons of transgenic mice with a mutant superoxide dismutase gene. Neurosci Lett 1998; 246: 153-156.
49. Baumgartner BJ, Shine HD. Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor. Exp Neurol 1998; 153: 102-112.
50. Baumgartner BJ, Shine HD. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J Neurosci 1997; 17: 6504-6511.
51. Lou J, Lenke LG, Xu F, O'Brien M. In vivo Bcl-2 oncogene neuronal expression in the rat spinal cord. Spine (Phila Pa 1976) 1998; 23: 517-523.
52. Zhang Y, Dijkhuizen PA, Anderson PN, Lieberman AR, Verhaagen J. NT-3 delivered by an adenoviral vector induces injureddorsal root axons to regenerate into the spinal cord of adult rats. J Neurosci Res 1998; 54: 554-562.
53. Namikawa K, Honma M, Abe K, et al. Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 2000; 20: 2875-2886.
54. Nakajima H, Uchida K, Kobayashi S, et al. Rescue of rat anterior horn neurons after spinal cord injury by retrograde transfection of adenovirus vector carrying brain-derived neurotrophic factor gene. J Neurotrauma 2007; 24: 703-712.
55. Watabe K, Ohashi T, Sakamoto T, et al. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res 2000; 60: 511-519.
56. Martinov VN, Sefland I, Walaas SI, Lomo T, Nja A, Hoover F. Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectors. Anat Embryol (Berl) 2002; 205: 215-221.
57. Glatzel M, Flechsig E, Navarro B, et al. Adenoviral, adenoassociated viral transfer of genes to the peripheral nervous system. Proc Natl Acad Sci USA 2000; 97: 442-447.
58. Zhang Y, Zheng Y, Zhang YP, et al. Enhanced adenoviral gene delivery to motor and dorsal root ganglion neurons following injection into demyelinated peripheral nerves. J Neurosci Res 2010; 88: 2374-2384.
59. Byrnes AP, Rusby JE, Wood MJ, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015-1024.
60. Byrnes AP, MacLaren RE, Charlton HM. Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 1996; 16: 3045-3055.
61. Hermens WT, Verhaagen J. Adenoviral vector-mediated gene expression in the nervous system of immunocompetent Wistar and T cell-deficient nude rats: preferential survival of transduced astroglial cells in nude rats. Hum Gene Ther 1997; 8: 1049-1063.
62. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected longterm brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97: 7482-7487.
63. Terashima T, Oka K, Kritz AB, Kojima H, Baker AH, Chan L. DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J Clin Invest 2009; 119: 2100-2112.
64. Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-11388.
65. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
66. Fleming J, Ginn SL, Weinberger RP, Trahair TN, Smythe JA, Alexander IE. Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum Gene Ther 2001; 12: 77-86.
67. Stam FJ, MacGillavry HD, Armstrong NJ, et al. Identification of candidate transcriptional modulators involved in successful regeneration after nerve injury. Eur J Neurosci 2007; 25: 3629-3637.
68. Mason MR, Ehlert EM, Eggers R, et al. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther 2010; 18: 715-724.
69. Wong LF, Yip PK, Battaglia A, et al. Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci 2006; 9: 243-250.
70. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-417.
71. Jacquet BV, Patel M, Iyengar M, et al. Analysis of neuronal proliferation, migration and differentiation in the postnatal brain using equine infectious anemia virus-based lentiviral vectors. Gene Ther 2009; 16: 1021-1033.
72. Mentis GZ, Gravell M, Hamilton R, Shneider NA, O'Donovan MJ, Schubert M. Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. J Neurosci Methods 2006; 157: 208-217.
73. Federici T, Kutner R, Zhang XY, et al. Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther 2009; 7:1.: 1.
74. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5: 387-398.
75. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994; 8: 148-154.
76. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell typespecific promoters. Gene Ther 1997; 4: 16-24.
77. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996; 713: 99-107.
78. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9: 2745-2760.
79. Hermens WT, ter BO, Dijkhuizen PA, et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999; 10: 1885-1891.
80. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-985.
81. Oranje PPA, Verheesen P, Verbart D, et al. Isolation of an Adeno-Associated Virus (AAV)-Specific Camelid-Derived Single Chain Antibody Fragment: A Novel Tool for Purification of AAV Vectors of Different Serotypes. Mol Ther 2004; 9: S162.
82. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167.
83. Xu Y, Gu Y, Wu P, Li GW, Huang LY. Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum Gene Ther 2003; 14: 897-906.
84. Xu Y, Gu Y, Xu GY, Wu P, Li GW, Huang LY. Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception. Proc Natl Acad Sci U S A 2003; 100: 6204-6209.
85. Andrews MR, Czvitkovich S, Dassie E, et al. Alpha9 integrin promotes neurite outgrowth on tenascin-C and enhances sensory axon regeneration. J Neurosci 2009; 29: 5546-5557.
86. Lorber B, Howe ML, Benowitz LI, Irwin N. Mst3b, an Ste20-like kinase, regulates axon regeneration in mature CNS and PNS pathways. Nat Neurosci 2009; 12: 1407-1414.
87. Leaver SG, Cui Q, Plant GW, et al. AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells. Gene Ther 2006; 13: 1328-1341.
88. Storek B, Harder NM, Banck MS, et al. Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats. Mol Pain 2006; 2:4.: 4.
89. Storek B, Reinhardt M, Wang C, et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A 2008; 105: 1055-1060.
90. Iwamoto N, Watanabe A, Yamamoto M, et al. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med 2009; 11: 498-505.
91. Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain 2009; 5: 52-68.
92. Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Bueler H. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet 2000; 9:803-811.
93. Lepore AC, Haenggeli C, Gasmi M, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 2007; 1185: 256-265.
94. Blits B, Carlstedt TP, Ruitenberg MJ, et al. Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brainderived neurotrophic factor. Exp Neurol 2004; 189: 303-316.
95. De Wit J, Eggers R, Evers R, Castren E, Verhaagen J. Long-term adeno-associated viral vector-mediated expression of truncated TrkB in the adult rat facial nucleus results in motor neuron degeneration. J Neurosci 2006; 26: 1516-1530.
96. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842.
97. Boulis NM, Noordmans AJ, Song DK, et al. Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiol Dis 2003; 14: 535-541.
98. Pirozzi M, Quattrini A, Andolfi G, et al. Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of hereditary spastic paraplegia. J Clin Invest 2006; 116: 202-208.
99. Hollis ER, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH. Efficient retrograde neuronal transduction utilizing selfcomplementary AAV1. Mol Ther 2008; 16: 296-301.
100. Hollis ER, Jamshidi P, Lorenzana AO, et al. Transient Demyelination Increases the Efficiency of Retrograde AAV Transduction. Mol Ther 2010; 18: 1496-1500.
101. Fortun J, Puzis R, Pearse DD, Gage FH, Bunge MB. Muscle injection of AAV-NT3 promotes anatomical reorganization of CST axons and improves behavioral outcome following SCI. J Neurotrauma 2009; 26: 941-953.
102. Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008; 16: 1018-1025.
103. Towne C, Schneider BL, Kieran D, Redmond DE, Jr., Aebischer P. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 2010; 17: 141-146.
104. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65.
105. Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010; 2: 35ra42.
106. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271-274.
107. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-1196.
108. Vulchanova L, Schuster DJ, Belur LR, et al. Differential adenoassociated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol Pain 2010; 6: 31.
109. Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120: 1253-1264.
110. Zheng H, Qiao C, Wang CH, et al. Efficient retrograde transport of adeno-associated virus type 8 to spinal cord and dorsal root ganglion after vector delivery in muscle. Hum Gene Ther 2010; 21: 87-97.
111. Haastert K, Mauritz C, Matthies C, Grothe C. Autologous adult human Schwann cells genetically modified to provide alternative cellular transplants in peripheral nerve regeneration. Journal of Neurosurgery 2006; 104: 778-786.
112. Haastert K, Mauritz C, Chaturvedi S, Grothe C. Human and rat adult Schwann cell cultures: fast and efficient enrichment and highly effective non-viral transfection protocol. Nature Protocols 2007; 2: 99-104.
113. Haastert K, Lipokatic E, Fischer M, Timmer M, Grothe C. Differentially promoted peripheral nerve regeneration by grafted Schwann cells over-expressing different FGF-2 isoforms. Neurobiol Disease 2006; 21: 138-153.
114. Haastert K, Grosheva M, Angelova SK, et al. Schwann Cells Overexpressing FGF-2 Alone or Combined with Manual Stimulation Do Not Promote Functional Recovery after Facial Nerve Injury. J Biomed Biotechnol 2009; 2009: 408794.
115. Li Q, Ping P, Jiang H, Liu K. Nerve conduit filled with GDNF gene-modified Schwann cells enhances regeneration of the peripheral nerve. Microsurgery 2006; 26: 116-121.
116. Hu Y, Leaver SG, Plant GW, et al. Lentiviral-mediated transfer of CNTF to schwann cells within reconstructed peripheral nerve grafts enhances adult retinal ganglion cell survival and axonal regeneration. Mol Ther 2005; 11: 906-915.
117. Gravvanis AI, Lavdas A, Papalois AE, et al. Effect of genetically modified Schwann cells with increased motility in end-to-side nerve grafting. Microsurgery 2005; 25: 423-432.
118. Aspalter M, Vyas A, Feiner J, Griffin J, Brushart T, Redett R. Modification of Schwann cell gene expression by electroporation in vivo. J Neurosci Methods 2009; 176: 96-103.
119. Shy ME, Tani M, Shi YJ, et al. An adenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve. Ann Neurol 1995; 38: 429-436.
120. Guenard V, Schweitzer B, Flechsig E, et al. Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 1999; 25: 165-178.
121. Dijkhuizen PA, Pasterkamp RJ, Hermens WT, de WF, Giger RJ, Verhaagen J. Adenoviral vector-mediated gene delivery to injured rat peripheral nerve. J Neurotrauma 1998; 15: 387-397.
122. Zhu JY, Huang YT, Zhu QS, Lu R. Expression of adenovirusmediated neurotrophin-3 gene in Schwann cells of sciatic nerve in rats. Chin J Traumatol 2003; 6: 75-80.
123. Li Z, Peng J, Wang G, et al. Effects of local release of hepatocyte growth factor on peripheral nerve regeneration in acellular nerve grafts. Exp Neurol 2008; 214: 47-54.
124. Bangari DS, Mittal SK. Current strategies and future directions or eluding adenoviral vector immunity. Curr Gene Ther 2006; 6: 215-226.
125. Lundberg C, Bjorklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461-473.
126. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes longterm expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-3709.
127. Ossevoort M, Visser BM, van den Wollenberg DJ, et al. Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther 2003; 10: 2020-2008.
128. Hendriks WT, Eggers R, Carlstedt TP, et al. Lentiviral vectormediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune stealth transgene. Restor Neurol Neurosci 2007; 25: 585-599.
129. Eggers R, Hendriks WT, Tannemaat MR, et al. Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots. Mol Cell Neurosci 2008; 39: 105-117.
130. Tannemaat MR, Eggers R, Hendriks WT, et al. Differential effects of lentiviral vector-mediated overexpression of nerve growth factor and glial cell line-derived neurotrophic factor on regenerating sensory and motor axons in the transected peripheral nerve. Eur J Neurosci 2008; 28: 1467-1479.
131. Jin Y, Ziemba KS, Smith GM. Axon growth across a lesion site along a preformed guidance pathway in the brain. Exp Neurol 2008; 210: 521-530.
132. Taylor L, Jones L, Tuszynski MH, Blesch A. Neurotrophin-3 gradients established by lentiviral gene delivery promote shortdistance axonal bridging beyond cellular grafts in the injured spinal cord. J Neurosci 2006; 26: 9713-9721.
133. Triolo D, Dina G, Lorenzetti I, et al. Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J Cell Sci 2006; 119: 3981-3993.
134. Tannemaat MR, Boer GJ, Verhaagen J, Malessy MJ. Genetic modification of human sural nerve segments by a lentiviral vector encoding nerve growth factor. Neurosurgery 2007; 61: 1286-1294.
135. Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgeneindependent manner. Mol Ther 2008; 16: 124-130.
136. Lai Y, Yue Y, Duan D. Evidence for the failure of adenoassociated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010; 18: 75-79.
137. Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010; 18: 87-92.
138. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010; 18: 80-86.
139. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10: 2112-2118.
140. De Palma M, Montini E, Santoni de Sio FR, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005; 105: 2307-2315.
141. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
142. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-353.
143. Nightingale SJ, Hollis RP, Pepper KA, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006; 13: 1121-1132.
144. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
145. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477.
146. Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther 2007; 15: 1740-1743.
147. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369: 2097-2105.
148. Hadaczek P, Forsayeth J, Mirek H, et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 2009; 20: 225-237.
149. Slepushkin V, Chang N, Cohen R, et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocess J 2003; 2: 89-95.
150. Segura MM, Kamen A, Garnier A. Purification of retrovirus particles using heparin affinity chromatography. Methods Mol Biol 2008; 434: 1-11.
151. Davidson BL, Stein CS, Heth JA, et al. Recombinant adenoassociated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000; 97: 3428-3432.
152. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82: 5887-5911.
153. Perabo L, Huber A, Marsch S, Hallek M, Buning H. Artificial evolution with adeno-associated viral libraries. Comb Chem High Throughput Screen 2008; 11: 118-126.
154. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24: 198-204.
155. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 2004; 78: 4421-4432.
156. Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21: 1040-1046.
157. Perabo L, Buning H, Kofler DM, et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157.
158. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
159. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009; 16: 311-319.
160. Varenika V, Kells AP, Valles F, Hadaczek P, Forsayeth J, Bankiewicz KS. Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res 2009; 175: 163-172.
161. Aartsen WM, van Cleef KWR, Pellissier LP, et al. GFAP-driven GFP Expression in Activated Mouse Müller Glial Cells Aligning Retinal Blood Vessels Following Intravitreal Injection of AAV2/6 Vectors. PLoS.One. 2010; 5: e12387.
162. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 2003; 311: 89-95.
163. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
164. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
165. Blesch A, Conner J, Pfeifer A, et al. Regulated lentiviral NGF gene transfer controls rescue of medial septal cholinergic neurons. Mol Ther 2005; 11: 916-925.
166. Markusic DM, de Waart DR, Seppen J. Separating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in rats. PLoS One 2010; 5: e9974.
167. Favre D, Blouin V, Provost N, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhumanprimates after intramuscular injection of recombinant adenoassociated virus. J Virol 2002; 76: 11605-11611.
168. Wang Y, O'Malley BW, Jr., Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994; 91: 8180-8184.
169. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996; 93: 3346-3351.
170. Zaldumbide A, Weening S, Cramer SJ, Rabelink MJ, Verhaagen J, Hoeben RC. A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator. Biotechnol Lett 2010; 32: 749-754.
171. Cao L, Lin EJ, Cahill MC, Wang C, Liu X, During MJ. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med 2009; 15: 447-454.
172. Raivich G, Bohatschek M, Da CC, et al. The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron 2004; 43: 57-67.
173. Seijffers R, Mills CD, Woolf CJ. ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci 2007; 27: 7911-7920.
174. Moore DL, Blackmore MG, Hu Y, et al. KLF family members regulate intrinsic axon regeneration ability. Science 2009; 326: 298-301.
175. Zou H, Ho C, Wong K, Tessier-Lavigne M. Axotomy-induced Smad1 activation promotes axonal growth in adult sensory neurons. J Neurosci 2009; 29: 7116-7123.
176. Stam FJ, Mason MR, Smit AB, Verhaagen J. A meta-analysis of large-scale gene expression studies of the injured PNS: toward the genetic networks that govern successful regeneration. In: Muller HW (Ed), Neural degeneration and repair: gene expression profiling, proteomics and systems biology. Hoboken, NJ: Wiley 2008; pp. 35-60
177. MacGillavry HD, Stam FJ, Sassen MM, et al. NFIL3 and cAMP response element-binding protein form a transcriptional feedforward loop that controls neuronal regeneration-associated gene expression. J Neurosci 2009; 29: 15542-15550.
178. Michaelevski I, Segal-Ruder Y, Rozenbaum M, et al. Signaling to transcription networks in the neuronal retrograde injury response. Sci Signal 2010; 3: ra53.
179. Lindwall C, Kanje M. Retrograde axonal transport of JNK signaling molecules influence injury induced nuclear changes in p-c-Jun and ATF3 in adult rat sensory neurons. Mol Cell Neurosci 2005; 29: 269-282.
180. Jimenez CR, Stam FJ, Li KW, et al. Proteomics of the injured rat sciatic nerve reveals protein expression dynamics during regeneration. Mol Cell Proteomics 2005; 4: 120-132.
181. Araki T, Nagarajan R, Milbrandt J. Identification of genes induced in peripheral nerve after injury. Expression profiling and novel gene discovery. J Biol Chem 2001; 276: 34131-34141.
182. Bosse F, Hasenpusch-Theil K, Kury P, Muller HW. Gene expression profiling reveals that peripheral nerve regeneration is a consequence of both novel injury-dependent and reactivated developmental processes. J Neurochem 2006; 96: 1441-1457.
183. Kubo T, Yamashita T, Yamaguchi A, Hosokawa K, Tohyama M. Analysis of genes induced in peripheral nerve after axotomy using cDNA microarrays. J Neurochem 2002; 82: 1129-1136.